We are currently working to bring into the upcoming ProhostBiotech Letter some small clinical and commercial innovating firms that are challenging the Top-Tier firms that are currently generating billions of dollars in selling revenues.  These firms are developers of products for treating  type 2 diabetes, obesity and NASH diseases, in addition to clinical stage firms that are challenging the current developers of gene editing diseases using their own techniques that differ from the Crispr technology.  

While doing this homework, we have been eager to hear important news from the FDA about the small dermatology firm Verrica Pharmaceuticals, which focuses . . .